Skip to main content
Clinical Trials/ISRCTN04761234
ISRCTN04761234CompletedNot Applicable

Bronchoscopic Lung Volume Reduction with endobronchial valves for patients with Heterogeneous emphysema and intact Interlobar FIssures

Imperial College London (UK)0 sites50 target enrollmentStarted: February 29, 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Adult patients with stable severe COPD (GOLD stage III or IV with FEV1<50%pred)
  • 2. Medical Research Council (MRC) dyspnoea score between 3 and 5
  • 3. Total lung capacity (TLC)>100%predicted, residual volume (RV)>150% predicted
  • 4. Six minute walk distance of <450m
  • 5. Patients will be on optimum medical therapy including inhaled corticosteroids and long acting beta 2 agonist and anti-cholinergic agents unless they are intolerant or decline to use them
  • 6. CT thorax must demonstrate heterogeneous emphysema with a defined target lobe with lung destruction and intact adjacent interlobar fissures. Scans will be reviewed by 2 radiologists independently and a third will adjudicate on any disagreements. Radiologists will have to agree that the worst affected lobe of the lung has an emphysema score of >2 (according to the NETT study scoring system), that it is at least 1 point higher than ipsilateral lobes and that it has intact fissures visible on at least one projection

Exclusion Criteria

  • 1. Significant co morbidity which limits their exercise capacity or prognosis
  • 2. Significant daily sputum production
  • 3. Hypoxia (i.e. PO2<6.5Pa)

Investigators

Sponsor
Imperial College London (UK)

Similar Trials

Bronchoscopic lung volume reduction for... | Clinical Trial